Pre Exposure Prophylaxis News and Research

RSS

Doxycycline increases antimicrobial resistance in the gut without disrupting microbiome diversity

Doxycycline post-exposure prophylaxis increases tetracycline resistance genes in the gut, without significantly affecting microbiome diversity in men who have sex with men and transgender women.

7 Oct 2024

Single dose of MVA-BN vaccine offers 58% protection against mpox

Researchers confirm the effectiveness of the modified vaccinia Ankara-Bavarian Nordic vaccine against mpox.

16 Sep 2024

Mpox persists in England: Strong vaccine effectiveness, stay vigilant

Study found that mpox cases in England remained low but steady in 2023, with the MVA-BN vaccine showing 82% effectiveness in preventing severe disease, particularly among GBMSM.

29 Aug 2024

UMass Amherst and Tufts Medical Center launch study to improve HIV care for incarcerated individuals

The University of Massachusetts Amherst and Tufts Medical Center are conducting a study to provide HIV prevention, diagnosis and treatment for people with opioid use disorders who are incarcerated in the Boston area.

9 Aug 2024

Reliability of HIV viral load tests for CAB-LA PrEP questioned in new study

A single laboratory-based HIV viral load test used by U.S. clinicians who provide people with long-acting, injectable cabotegravir (CAB-LA) HIV pre-exposure prophylaxis (PrEP) did not reliably detect HIV in a multi-country study.

23 Jul 2024

Long-acting injectable CAB-LA safe for HIV PrEP during pregnancy, study finds

Long-acting injectable cabotegravir (CAB-LA) was safe and well tolerated as HIV pre-exposure prophylaxis (PrEP) before and during pregnancy in the follow-up phase of a global study among cisgender women.

23 Jul 2024

PrEPVacc HIV vaccine trial shows no reduction in infections

The results of the PrEPVacc HIV vaccine trial conducted in Eastern and Southern Africa, which ran between 2020 and 2024, show conclusively that neither of the two experimental vaccine regimens tested reduced HIV infections among the study population.

23 Jul 2024

Lenacapavir: A breakthrough in long-acting HIV prevention for cisgender women

The injectable antiretroviral drug lenacapavir was safe and 100% effective as long-acting HIV pre-exposure prophylaxis (PrEP) among cisgender women in a Phase 3 clinical trial, according to top-line findings released by Gilead Sciences, Inc., the study sponsor.

26 Jun 2024

ChatGPT could be an effective tool to help reduce vaccine hesitancy

New research being presented at this year's ESCMID Global Congress (formerly ECCMID) in Barcelona, Spain (27-30 April) suggests that the free-to-use, widely accessible ChatGPT could be an effective tool to help reduce vaccine hesitancy among the general public, as well as providing helpful advice on sexually transmitted infections (STIs) in conjunction with sexual health clinics, by improving knowledge and access to care.

10 Apr 2024

New report on HIV drug resistance: Challenges and recommendations

The World Health Organization's (WHO) latest HIV Drug Resistance (HIVDR) Report tells us where drug resistance is growing and offers recommendations for countries to monitor and respond to the potential challenges.

1 Apr 2024

Case study: Monkeypox breakthrough infection in fully vaccinated individual

New research to be presented at this year's European Congress of Clinical Microbiology and Infectious Diseases in Barcelona, Spain (27-30 April) details the case of a man who had received two doses of the monkey pox vaccine in Autumn, 2022 yet experienced a 'breakthrough' mpox infection in January 2024.

1 Apr 2024

Rethinking PrEP's role in prevention of sexually transmitted infections

In their research article published in Eurosurveillance, von Schreeb et al. challenge existing assumptions regarding the relationship between the use of HIV pre-exposure prophylaxis (PrEP) and the incidence of bacterial sexually transmitted infections (STI).

28 Mar 2024

Vaginal ring and oral PrEP found to be safe for HIV prevention among pregnant cisgender women

The monthly dapivirine vaginal ring and daily oral pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine were each found to be safe for HIV prevention among cisgender women who started using one of them in their second trimester of pregnancy, according to findings presented today at the 2024 Conference on Retroviruses and Opportunistic Infections (CROI) in Denver.

5 Mar 2024

Combination interventions increase PrEP uptake among at-risk youth, study shows

A UCLA Health-led study found a combination of interventions of one-on-one telehealth coaching, peer support forums, and automated text messages more than doubled the use of the HIV prevention strategy, called PrEP, among younger, at-risk Americans, a group that historically has had low use of the medication.

22 Feb 2024

Combined vaccination and behavior change efforts averted 64% of US mpox cases, study reveals

The effectiveness of the combination of current preventive responses against monkeypox (Mpox).

10 Jan 2024

Rising out-of-pocket costs for PrEP threaten key strategy in ending the HIV epidemic

Increasing patients' out of pocket costs for HIV pre-exposure prophylaxis (PrEP), medications, which have been shown to dramatically reduce the risk of HIV infection, could lead to a significant reduction in PrEP use and a rise in HIV infection rates, according to a new study co-led by researchers at the Perelman School of Medicine at the University of Pennsylvania and Johns Hopkins Bloomberg School of Public Health.

8 Jan 2024

New early phase study evaluates “on-demand” HIV prevention method for women

A fast-dissolving vaginal insert that women would use at or around the time of sex as an "on-demand" HIV prevention method is being evaluated in a new early phase study being conducted by MATRIX, a United States Agency for International Development (USAID)-funded project focused on the early research and development of innovative HIV prevention products for women.

7 Dec 2023